Production (Stage)
Tonix Pharmaceuticals Holding Corp.
TNXP
$28.93
$2.539.58%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 10.04M | 10.09M | 11.29M | 12.46M | 10.25M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.04M | 10.09M | 11.29M | 12.46M | 10.25M |
| Cost of Revenue | 7.05M | 7.77M | 8.95M | 9.77M | 6.40M |
| Gross Profit | 2.99M | 2.33M | 2.34M | 2.69M | 3.85M |
| SG&A Expenses | 40.90M | 40.10M | 36.14M | 37.15M | 36.67M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 82.49M | 87.84M | 93.88M | 107.64M | 116.08M |
| Operating Income | -72.45M | -77.74M | -82.59M | -95.19M | -105.83M |
| Income Before Tax | -131.93M | -130.04M | -135.25M | -149.01M | -98.59M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -131.93 | -130.04 | -135.25 | -149.01 | -98.59 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -131.93M | -130.04M | -135.25M | -149.01M | -98.59M |
| EBIT | -72.45M | -77.74M | -82.59M | -95.19M | -105.83M |
| EBITDA | -69.51M | -74.29M | -78.61M | -90.73M | -101.42M |
| EPS Basic | -1.96K | -2.50K | -4.67K | -4.64K | -2.72K |
| Normalized Basic EPS | -325.18 | -658.45 | -652.34 | -638.04 | -334.82 |
| EPS Diluted | -1.96K | -2.50K | -4.67K | -4.64K | -2.72K |
| Normalized Diluted EPS | -325.18 | -658.45 | -652.34 | -638.04 | -334.82 |
| Average Basic Shares Outstanding | 8.85M | 2.95M | 690.00K | 68.80K | 27.90K |
| Average Diluted Shares Outstanding | 8.85M | 2.95M | 702.50K | 81.30K | 40.40K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |